Clinical Trial Update: Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating luspatercept with or without hydroxyurea for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Myeloproliferative Neoplasm Not Otherwise Specified
• Myelodysplastic Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Luspatercept (luspatercept)

Snippet

Sponsor: Mayo Clinic | Conditions: Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19